Low-molecular-weight heparin (LMWH) has enhanced anticoagulant efficacy, long duration of action, and extended half-life, but achieving long-term efficacy is challenging. Here, the authors design and evaluate a nanoengineered LMWH and octadecylamine conjugate (LMHO) that can act for a long time while maintaining close to 97% of LMWH activity via end specific conjugation of the reducing end of LMWH.
- Jae-Hyeon Lee
- Hansol Lim
- Jooho Park
